[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-dysfunction":48},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,90,0,25,[9,81,141,178,228,255,282,307,339,364,393,418,447,472,500,521,544,566,602,625,652,680,713,740,774],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":57,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100454745","interventions-in-mathematics-and-cognitive-skills-100454745",false,"NCT05201534","Interventions in Mathematics and Cognitive Skills","Interventions in Math Learning Disabilities: Cognitive and Neural Correlates","Inclusion Criteria:\n\n1. Elementary school aged children starting from first grade (6-12 years old)\n2. IQ: Participants with a Full Scale IQ \\> 70 on the Wechsler Abbreviated Scle of Intelligence (WASI-II).\n3. Identification of Mathematical Learning Disabilities: Scores below the 35th percentile percentile on symbolic number processing test in Numeracy Screener and two or more Wechsler Individual Achievement Test (WIAT-IV) math subtests\n4. Identification of typically developing children: Scores at or above the 35th percentile percentile on symbolic number processing test in Numeracy Screener and all WIAT-IV math subtests\n5. Normal or corrected-to-normal vision and no hearing impairments\n6. Inclusion in MRI scan session: Right-handed\n\nExclusion Criteria:\n\n1. History of neurological or psychiatric disorder (i.e., schizophrenia, psychosis, depression, or attention deficit hyperactivity disorder.)\n2. History of trauma involving head injury\n3. Consistent psychiatric medications\n4. Exclusion from MRI scan session: No major contraindication for magnetic resonance imaging (MRI) - braces, metal implants, pacemakers, vascular stents, metallic ear tubes, consistent exposure to metal, claustrophobia)",true,"ALL","6 Years","12 Years",{"count":22,"type":23},180,"ESTIMATED","INTERVENTIONAL",[26],"NA","The purpose of this study is to investigate neurocognitive mechanisms underlying response to intervention aimed at enhancing, and remediating weaknesses in, numerical skills in children, including those with mathematical learning disabilities (MLD).",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56],"Math Learning Disability","Child Development","Developmental Disability","Learning Disabilities","Learning Disabled","Learning Curve","Mathematics Disorder","Dyscalculia","Dyscalculia, Primary","Dyscalculia, Acquired","Specific Learning Disorder, With Impairment in Mathematics","Individuality","Behavior, Child","Behavior and Behavior Mechanisms","Behavior","Decision Making","Neuronal Plasticity","Cognition","Cognition Disorder","Cognitive Dysfunction","Cognitive Change","Cognitive Impairment, Mild","Cognitive Developmental Delay","Cognitive Orientation","Cognitive Delay, Mild","Cognitive Deficits, Mild","Cognitive Abnormality","Neuroscience",[58,59,60,61,62,63,64,65,66,67],"Numerical skills in children","Low math abilities","Mathematical Learning Disabilities","Mathematical Concepts","Mathematics","Transfer, Psychology","Generalization, Psychology","Early Intervention, Educational","Neural Pathways","Neural Networks, Computer","RECRUITING","2026-06-22",{"date":71,"type":72},"2026-06-25","ACTUAL",{"date":74,"type":72},"2023-05-05",{"date":76,"type":23},"2026-08-31",{"name":78,"class":79},"Stanford University","OTHER",1,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":17,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":92,"briefSummary":93,"conditions":94,"keywords":109,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":80},"100643981","health-ahead-comparative-effectiveness-study-100643981","NCT07669168","Health Ahead Comparative Effectiveness Study","Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening","HACE","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up.\n\nExclusion Criteria:\n\n\\- Age under 18 years.","18 Years",{"count":91,"type":23},1000000,[26],"The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening - each isolated as a single variable against current practice - on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, allowing results to accumulate on a consistent yardstick across the life of the platform.\n\nThe first comparison evaluates static versus interactive personalized health report delivery. Subsequent pre-planned comparisons, added by protocol amendment, evaluate mobile community versus fixed laboratory screening; and a hybrid medical-droid plus human-delivery model versus human-only screening. All participants are simultaneously enrolled in the 100-Year Human Aging Study and the Human Observatory Study, contributing individual longitudinal and population-level causal inference data through those protocols.",[95,96,97,98,99,100,101,102,103,48,104,105,106,107,108],"Health Services Accessibility","Rural Health","Medically Underserved Area","Preventive Health Services","Patient Participation","Health Behavior","Aging","Cardiovascular Diseases","Metabolic Syndrome","Frailty","Activities of Daily Living","Health Related Quality of Life","Health Equity","Telemedecine",[110,111,112,113,114,107,96,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131],"Sequential Platform Trial","Interactive Health Report","Health Activation","Mobile Health Screening","Comparative Effectiveness","Medically Underserved","Preventive Medicine","Patient Engagement","Cardiopulmonary Exercise Testing","Body Composition","DEXA","Health Ahead Bus","Mobile Clinic","Automated Screening","Medical Droids","Biological Age","Healthspan","Longevity","Life Expectancy","Chronic Disease","Cost-Effectiveness","Health Services Research","2026-06-20",{"date":71,"type":72},{"date":135,"type":23},"2026-06-09",{"date":137,"type":23},"2099-12-31",{"name":139,"class":140},"William Brandenburg, MD","INDUSTRY",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":24,"phases":152,"briefSummary":154,"conditions":155,"keywords":159,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100642012","phase-2-a-study-of-donanemab-ly3002813-in-participants-with-early-cognitive-decline-trailblazer-alz-7-100642012","NCT07589595","A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)","A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology","Inclusion Criteria:\n\n* Have gradual and progressive cognitive decline for greater than or equal to ( ≥) 6 months.\n* Have least 1 core clinical feature of dementia with Lewy bodies (DLB).\n* Have a score ≥20 on Montreal Cognitive Assessment (MoCA).\n* Meet plasma P-tau217 criteria.\n* Have a cerebrospinal fluid (CSF) result consistent with the presence of brain amyloid pathology.\n* Have a CSF result consistent with the presence of alpha-synuclein pathology.\n* Have at least 1 reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant, and is familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n\nExclusion Criteria:\n\n* Have a disease or condition that could interfere with this study or is a current serious or unstable illness.\n* Have, or is suspected to have, a significant neurological disease (other than the studied condition) that affects the central nervous system and may affect the individual's cognition or ability to complete the study.\n* Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence and preventing the completion of the study.\n* Have clinically significant multiple or severe drug allergies, significant atopy, or severe posttreatment hypersensitivity reactions.\n* Have previously received amyloid-targeting therapy.\n* Active immunization against amyloid-beta.\n* Have a centrally read MRI that does not meet study entry criteria.\n* Have contraindication to MRI or PET scans.\n* Have any contraindication to lumbar puncture.","55 Years","85 Years",{"count":151,"type":23},350,[153],"PHASE2","The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.",[48,156,157,158],"Lewy Body Disease","Synucleinopathies","Amyloid",[160,161,162,163,164,165,166,167,48],"Mild Cognitive Impairment","Mild Dementia","Brain Diseases","Nervous System Diseases","Neurodegenerative Diseases","Neurocognitive Disorders","Cognition Disorders","Alzheimer Disease","2026-06-16",{"date":170,"type":72},"2026-06-17",{"date":172,"type":72},"2026-05-20",{"date":174,"type":23},"2028-08",{"name":176,"class":140},"Eli Lilly and Company",72,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":17,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":188,"conditions":189,"keywords":200,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":80},"100641995","human-observatory-study-100641995","NCT07646782","Human Observatory Study","The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity","HOS","Inclusion Criteria:\n\n* Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.\n\nExclusion Criteria:\n\n* Age under 18 years (current protocol; pediatric amendment planned).",{"count":91,"type":23},"OBSERVATIONAL","The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. Thus creating a feedback architecture designed to improve both simultaneously.",[101,190,191,128,102,192,48,103,104,193,194,195,105,106,196,197,198,107,199],"Mortality","All-cause Mortality","Neoplasms","Musculoskeletal Disease","Neurodegenerative Disease","Dementia","Disability Physical","Environmental Exposure","Occupational Diseases","Social Determinants of Health",[201,202,203,204,205,206,207,208,209,210,211,212,213,107,214,215,118,119,116,126,216,217,218,219,220],"longevity","biological aging","causal inference","life expectancy","exposome","Environmental Health","Social Determinants","Genealogy","Family History","Human Family Tree","Population Health","Neighborhood Health","Geographic Health Disparities","Mortality Prediction","Biomarker Validation","Functional Decline","Centenarian","Space Medicine","Aerospace Medicine","World Model",{"date":222,"type":72},"2026-06-15",{"date":224,"type":72},"2026-04-25",{"date":137,"type":23},{"name":227,"class":140},"Longevity Metrics, Inc.",{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":17,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":236,"conditions":237,"keywords":243,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":80},"100636291","100-year-human-aging-study-100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",{"count":91,"type":23},"The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[101,238,239,190,103,102,48,240,192,104,105,241,196,242,195],"Aging Well","All-Cause Mortality","Musculoskeletal Diseases","Health-Related Quality of Life","Neuro-Degenerative Disease",[127,118,119,116,244,214,216,126,128,245,246,247,215,248,211,217],"Surrogate Endpoint Validation","Biological Aging","Preventive Screening","Longitudinal Cohort","Human Performance",{"date":250,"type":72},"2026-06-11",{"date":252,"type":72},"2025-02-09",{"date":137,"type":23},{"name":227,"class":140},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":17,"sex":18,"minAge":263,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":24,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":80},"100555066","polyphenols-and-cognitive-decline-100555066","NCT06507254","Polyphenols and Cognitive Decline","MAEVE: Microbiota Mediated Flavonoid Metabolites for Cognitive Health","MAEVE","Inclusion Criteria:\n\n* 50+ Years of age\n* Male or Female\n* At enhanced risk of Alzheimer's Disease (defined as family history of AD, 1st degree family member)\n* Habitually consume suboptimal diets such as typical Western Diet (i.e., high in animal products, refined carbohydrates and processed food)\n* Able to communicate well in English\n\nExclusion Criteria:\n\n* Vegan or Vegetarian\n* Presence of cognitive impairment at the time of recruitment into the study as measured by the Mini Mental Status Exam (MMSE, score 25-30) and Clinical Dementia Rating (CDR, score=0).\n* Pre-existing psychosis or psychiatric conditions\n* Currently receiving treatment for dementia\n* History of alcohol and\u002For substance abuse\u002Fdependence as determined by a positive endorsement on the MINI+\u002F If the MINI+ is positive for alcohol or drug dependence, or abuse, the participants will be excluded.\n* Heavy use of tobacco (greater than 1\u002F2 pack per day)\n* History of cerebrovascular events\n* Existing allergies to berry fruits\n* Use of oral\u002FIV antibiotics in the last 3 months. Use of probiotics in the last 1 month.\n* Recent Changes (last 3 months) in the use of psychoactive medications or other medications that interfere with the measured outcomes.\n* Frailty, malnutrition, or food allergy\u002Fintolerance requiring special diets.\n* Body weight at enrollment greater than 400lbs due to weight restrictions on the MRI table.\n* Women who are pregnant, lactating, or postpartum for less than 6months.\n* Women of childbearing age who are not practicing birth control or are planning to get pregnant during the study.\n\nUnable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, metallic foreign body, etc.)\n\n* Chronic Pain","50 Years",{"count":265,"type":23},300,[26],"Globally, populations are aging thereby increasing healthcare burden, overall cognitive impairment, and dementia including Alzheimers diseases (AD). The lack of effective treatments makes it essential to develop new strategies for healthy cognitive aging, including interventions to slow or prevent cognitive decline. A traditional Mediterranean diet, rich in polyphenols (PPs), may prevent or delay the onset of cognitive dysfunction in older adults, preserving healthy brain structure and function, and lowering the risk of AD. These effects, mediated in part by gut microbiome-derived PP metabolites, highlight the role alterations in the brain-gut microbiome system play in neurodegeneration. Moreover, high levels of circulating phenyl-y-valerolactones, neuroprotective compounds, exclusively produced by gut microbiota from flavan-3-ol-rich foods (e.g., cocoa, tea, berries) are associated with delaying the onset of cognitive dysfunction in older adults. Intake of such PPs can also change gut microbial composition and function, altering the physiology of the hosts secondary bile acid (BA) pool, affecting regulatory and signaling functions in the brain as well as cognitive decline and AD. The investigators hypothesize that, in older adults with enhanced AD risk, dietary intake of PPs maintains healthier brain features and cognitive function, and that this beneficial effect is mediated by gut microbiota metabolites of PPs and BAs.\n\nIn this multi-PI application by leaders in the field of brain-gut microbiome interactions, the investigators will conduct a year-long, multi-center, randomized double-blind placebo-controlled study in 300 older adults in the United States (validation sample of 100 from Northern Ireland) who are at enhanced risk of developing AD. Ultimately, the investigators will establish the protective effects of regular dietary PP intake on cognitive function and on brain-gut microbiome interactions, ideally allowing the development of effective dietary regimes to prevent of delay the onset of AD in at-risk elderly, thereby reducing cognitive decline and healthcare costs.\n\nParticipants will be asked to provide information about their diet, mood, and behaviors via food diaries, physical body measures (e.g. height, weight, etc.), and online questionnaires collected before each in-clinic appointment, as well as monthly online questionnaires. MR imaging will be collected on participants to assess neurocognitive changes as a result of the supplement. Participants will be asked to provide both stool and blood samples. Participants will be randomly assigned to either the Juice Plus+ intervention group or the placebo treatment group and then asked to take their respective supplement 4 pills twice a day. All participants will be asked to come in for 4 in-clinic appointments, including 3 brain MRI scans and 3 cognitive testing appointments, collect 3 stool samples with corresponding diet diaries, and provide 3 blood samples over the course of 12 months. Participants will also meet with a nutritionist 3 times over the 12 months to discuss diet to ensure study eligibility and any questions about the supplement.",[269,48],"Cognitive Decline",[271,272,273,274],"Polyphenols","Mediterranean Diet","Gut Microbiome","Alzheimers Disease",{"date":250,"type":72},{"date":277,"type":72},"2025-01-09",{"date":279,"type":23},"2029-12-31",{"name":281,"class":79},"University of California, Los Angeles",{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":80},"100643034","vortioxetine-for-cognitive-function-in-alk-positive-nsclc-treated-with-lorlatinib-100643034","NCT07633626","Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib","Potential Effect of Vortioxetine on Cognitive Functioning of Patients With ALK-positive Non-Small Cell Lung Cancer Treated With Lorlatinib","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of ALK\u002FROS1-positive non-small cell lung cancer (NSCLC), stage IIIB\u002FIV.\n* Currently receiving lorlatinib as part of the standard therapeutic regimen.\n* Documented neurocognitive adverse events (NAEs) attributable to lorlatinib.\n* Age \\>= 18 years.\n* ECOG performance status 0-2.\n* Ability to understand and sign informed consent.\n* Expected survival \\>= 6 months.\n* Planned initiation of vortioxetine as part of standard care.\n* Ability to complete neuropsychological tests and questionnaires in Spanish.\n\nExclusion Criteria:\n\n* Prior diagnosis of major cognitive impairment unrelated to cancer treatment.\n* Current use of another antidepressant that cannot be discontinued.\n* Uncontrolled major psychiatric disorder.\n* History of uncontrolled epilepsy or recent seizures.\n* Severe hepatic or renal impairment.\n* Known hypersensitivity to vortioxetine.\n* Participation in another clinical trial within the past 30 days.\n* Inability to provide informed consent.\n* Life expectancy \\\u003C 3 months.\n* Contraindications to vortioxetine (e.g., concomitant MAOI use).\n* Prior vortioxetine use.\n* Severe psychiatric disorders or significant cognitive impairment unrelated to lorlatinib.",{"count":290,"type":23},24,"This observational study evaluates whether vortioxetine - an antidepressant medication with cognitive-enhancing properties - can reduce the neurological and cognitive side effects associated with lorlatinib treatment in patients with non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements.\n\nLorlatinib is a highly effective third-generation tyrosine kinase inhibitor, but it causes neuropsychological adverse events (NAEs) in approximately 42% of patients, including cognitive impairment, mood changes, and speech disturbances. Vortioxetine has demonstrated cognitive improvement in depressed patients and in preclinical models of androgen deprivation therapy-induced cognitive impairment.\n\nTwenty-four adult patients with ALK\u002FROS1-positive NSCLC receiving lorlatinib as standard care and prescribed vortioxetine (10-20 mg\u002Fday) for NAE management will be enrolled. Comprehensive neuropsychological assessments and quality-of-life questionnaires will be conducted at baseline, week 6, week 12, and month 6 to document changes in cognitive function, depressive symptoms, and quality of life.",[293,294,295,296,48,297],"Advanced ALK\u002FROS1-positive NSCLC","Carcinoma, Non-Small-Cell Lung (NSCLC)","Lung Adenocarcinoma","ALK-positive Non-small Cell Lung Cancer (NSCLC)","Depression","2026-06-04",{"date":300,"type":72},"2026-06-08",{"date":302,"type":72},"2026-03-10",{"date":304,"type":23},"2027-11-10",{"name":306,"class":79},"Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":24,"phases":316,"briefSummary":317,"conditions":318,"keywords":326,"overallStatus":331,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":80},"100633163","mecfs-brain-fog-cognitive-rehabilitation-trial-100633163","NCT07523113","ME\u002FCFS Brain Fog: Cognitive Rehabilitation Trial","Brain Training for Chronic, Post-viral, Brain Fog: Study A","Inclusion Criteria:\n\n* diagnosis of ME\u002FCFS that preceded cognitive complaints\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* some impairment in the performance of daily activities\n* ≥ 18 years, no upper limit if medically stable\n* reside in the community (as opposed to a hospital or skilled nursing facility)\n* able to travel to the laboratory on multiple occasions\n* has Internet service\n* has a personal computer, laptop, or tablet that can access the Internet\n* sufficiently fit, from both a physical and mental health perspective, to take part in the study\n* adequate sight and hearing to complete the UFOV test\n* adequate thinking skills, e.g., ability to follow directions and retain information to complete UFOV and CTAL, as marked by the judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\n* sufficient English proficiency (i.e., ability to speak, understand, read, and write to take part in study activities)\n\nExclusion Criteria:\n\n* cognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse, or due to another type of brain injury, such as traumatic brain injury, stroke, or a progressive brain disease, such as Alzheimer's Dementia\n* current substance abuse disorder\n* diagnosis of postural orthostatic tachycardia syndrome (POTS) by a healthcare provider\n* prior cognitive processing speed training on DoubleDecision or a similar program\n* cannot tolerate taVNS\n* prior history of heart attack or other serious cardiac events\n* implanted medical device of any type\n* vasovagal syncope or history of fainting\n* history of seizures or epilepsy\n* temporomandibular Joint (TMJ) syndrome or other conditions that cause substantial jaw pain\n* history of peripheral nerve injury to the head, neck, or face\n* pregnant or breastfeeding\n* not able or willing to get an MRI scan\n* not able or willing to get a blood draw",{"count":315,"type":23},30,[26],"The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog. All participants will be screened for eligibility prior to participation. Most of the procedures will take place over a phone call or secure telehealth platform (i.e., Zoom). However, participants will be asked to visit UAB on three occasions for blood sample collection and brain imaging (about 2 hours each). Online testing will happen one month before treatment, one day before treatment, one day afterwards, and 6 months afterwards. The study will utilize two different forms of rehabilitation training to improve participants' cognitive ability. Participants will be randomized to one of the two treatment groups. The first treatment approach, known as Constraint-Induced Cognitive Therapy (CICT), will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) online training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation, also known as trans-auricular VNS (taVNS). The second approach, known as Brain Fitness Training (BFT), will include (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, breathing, healthy nutrition, and healthy sleep, (C) education about how relaxation, breathing, nutrition, and sleep are connected to thinking effectiveness, and (D) taVNS. Approximately 30 hours of training will be conducted over a secure telehealth platform (i.e., Zoom) in the span of two- to four- weeks. A typical CICT session will consist of one hour of gaming, with the bulk of the session being spent on cognitive training of the target behaviors and procedures designed to promote transfer of therapeutic gains to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. A typical BFT session will consist of one hour of gaming, training on healthy lifestyle behaviors (i.e., healthy sleep, nutrition, and relaxation habits), as well as procedures designed to promote transfer of behavior changes to daily life. Ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. Training sessions in both conditions will be scheduled based on participants' availability, with the options for sessions scheduled to be as close as every weekday over 2 weeks or as loosely as every other weekday (i.e., over a 4-week span). If a caregiver is available, they will receive training on how to best support participants in their therapeutic program. After the training ends, both groups will receive 4 follow-up phone calls approximately one week apart to promote integration of the gained skills into everyday life. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.",[319,320,321,322,323,324,325,48],"ME\u002FCFS","ME\u002FCFS Following EBV-associated Infectious Mononucleosis","ME\u002FCFS Following COVID-19","Chronic Fatigue","Chronic Fatigue Syndrome (CFS)","Brain Fog","Cognitive Impairment",[319,322,327,325,48,328,329,330],"Brain fog","post-viral syndrome","Cognitive Rehabilitation","CICT","NOT_YET_RECRUITING",{"date":300,"type":72},{"date":334,"type":23},"2026-06",{"date":336,"type":23},"2028-06",{"name":338,"class":79},"University of Alabama at Birmingham",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":18,"minAge":346,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":24,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":363},"100503106","up-2-study-cognitively-engaging-walking-exercise-and-neuromodulation-to-enhance-brain-function-in-older-adults-100503106","NCT05830942","Up-2 Study: Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults","Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults","Inclusion Criteria:\n\n* Age 65+\n* Objective executive function decline, based on standardized cognitive assessments.\n* Subjective cognitive decline, based on the question: \"During the past 12 months, have you experienced confusion or memory loss that is happening more often or getting worse?\"\n* Ability to walking independently for 6 minutes (use of cane permitted)\n\nExclusion Criteria:\n\n* Major cognitive disorder that interferes with independence\n* Percentile score less than 10th percentile on standardized cognitive assessments\n* Medications that are thought to influence tDCS neuroplasticity.\n* Contraindications to tDCS or MRI.","65 Years",{"count":348,"type":23},120,[26],"Declines in cognitive function and walking function are highly intertwined in older adults. A therapeutic approach that combines complex (cognitively engaging) aerobic walking exercise with non-invasive electrical brain stimulation may be effective at restoring lost function. This study tests whether electrical stimulation of prefrontal brain regions is more beneficial than sham stimulation.",[48,352,353],"Mobility Limitation","Frail Elderly","2026-06-02",{"date":356,"type":72},"2026-06-03",{"date":358,"type":72},"2024-04-15",{"date":360,"type":23},"2027-04-30",{"name":362,"class":79},"University of Florida",2,{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":372,"maxAge":149,"enrollmentInfo":373,"targetDuration":4,"studyType":24,"phases":375,"briefSummary":376,"conditions":377,"keywords":380,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":80},"100633442","brain-stimulation-and-cognitive-training-for-mci-100633442","NCT07526740","Brain Stimulation and Cognitive Training for MCI","Combining Brain Stimulation With Computerized Cognitive Training for MCI","RISE pilot","Inclusion Criteria:\n\n1. Age 60-85 (inclusive).\n2. English as a first\u002Fprimary language.\n3. Adequate sensorimotor function and verbal expressive abilities to complete all assessments.\n4. Must have a co-participant (e.g. spouse, adult child or relative, sibling, cohabitator, friend, caregiver) who has at least weekly in-person contact with the participant and is willing to participate in the study as a collateral informant.\n5. Meets the following requirements for current and prior medications and treatments:\n\n   1. Is on fixed pharmacotherapy (i.e. stable dose of medication\u002Fs) for ≥ 4 weeks before enrollment. This includes, but is not limited to, cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants.\n   2. Anti-amyloid monoclonal antibody therapy for AD\u002FMCI:\n\n      * Prior treatment is permitted if last infusion occurred ≥ 8 weeks before enrollment.\n      * Current treatment is permitted if the dose has been stable for ≥ 12 weeks before enrollment, with no planned dose change during study participation.\n   3. Prior TMS treatment is permitted if the last stimulation session was ≥ 24 weeks before enrollment.\n6. Documented diagnosis of MCI per NIA-AA criteria or Mild Neurocognitive Disorder per DSM-5 criteria by a healthcare provider within the past year, with a presumed etiology of possible or probable AD 7. Met actuarial neuropsychological criteria for MCI43 within the past year (i.e. ≥2 impaired scores within one cognitive domain, or ≥1 impaired scores in ≥3 domains, where an impaired score is defined as ≤16th percentile using appropriate demographically-corrected norms).\n\nExclusion Criteria:\n\n1. Telephone Interview for Cognitive Status (TICS) score of ≤ 22 suggestive of dementia.\n2. Prior diagnosis of Dementia (NIA-AA) or Major Neurocognitive Disorder (DSM-5).\n3. Daily\u002Fweekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review.\n4. History of significant or unstable condition\u002Fs or treatments for these condition\u002Fs that may impact cognition (as determined by the study investigators) such as significant cardiac (e.g. heart failure), infectious (e.g. HIV, urinary tract infection), or metabolic disease (e.g. labile diabetes), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), severe mental illness (e.g., bipolar disorder, psychoses), alcohol or substance use disorder, developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury, seizures).\n5. Plan to initiate treatment for AD\u002FMCI with monoclonal antibody therapy during study participation.\n6. For those currently receiving monoclonal antibody therapy, documented history of clinically significant amyloid-related imaging abnormalities (ARIA) in their medical record.\n7. Current use of any implanted brain stimulation device.\n8. Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days that may impact cognition or mood.\n9. MRI contraindications (e.g., ferromagnetic implants, claustrophobia).\n10. Unable or unwilling to engage in BrainHQ activities.\n11. TMS contraindications (e.g., ferromagnetic implants, conditions or treatments that lower seizure threshold, taking medications that have short half-lives) or no identifiable motor threshold.","60 Years",{"count":374,"type":23},50,[26],"This is a randomized clinical trial of a treatment that combines non-invasive brain stimulation with computerized cognitive training (CCT) for people with mild cognitive impairment (MCI). The form of brain stimulation used in this study is accelerated intermittent theta burst stimulation (iTBS). All participants receive the same amount of iTBS and are randomly assigned to engage in one of two types of CCT. The goals of the study are to see if this combined treatment is feasible and acceptable to people with MCI and whether combined iTBS and CCT improves memory, thinking skills, mood, and daily function.",[378,379,165,48,166],"Mild Cognitive Impairment (MCI)","Mild Neurocognitive Disorder",[101,381,382,160,383,384],"Alzheimers","Memory Loss","Transcranial Magnetic Stimulation","cognitive training",{"date":386,"type":72},"2026-05-22",{"date":388,"type":72},"2026-03-16",{"date":390,"type":23},"2030-05-31",{"name":392,"class":79},"Medical University of South Carolina",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":18,"minAge":346,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":363},"100460246","mobility-disorders-assessment-in-patients-with-mild-cognitive-disorders-100460246","NCT05273125","MOBility Disorders Assessment in Patients With Mild COGnitive Disorders","Multimodal and Longitudinal Assessment of MOBility Disorders in Patients With Mild COGnitive Disorders","COG-MOB","Inclusion Criteria:\n\n* Patient being diagnosed with MCI, according to the 2011 criteria\n* Able to walk 4 meters with or without technical assistance\n* Comprehension of French language allowing the realization of the neuropsychological assessment\n\nExclusion Criteria:\n\n* Severe visual or hearing impairment that does not allow the assessment\n* Severe pathology that makes follow-up impossible\n* Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security insurance, refusal to sign consent form\n* Under legal protection (guardianship, curatorship, safeguard of justice)",{"count":402,"type":23},417,"Mild cognitive impairment (MCI) is defined by lower performance in one or more cognitive domains with preservation of independence in functional abilities. Sixteen percent of community-dwelling older people (over 65 years) live with MCI. They are both cognitively and physically vulnerable. From a cognitive perspective, they are susceptible to converting to the dementia stage at an annual rate of 10%. From a physical perspective, the proportion of slow gait or neurological gait abnormalities can reach 46% in the population with MCI. Falls in turn increase the risk of accelerated cognitive decline and the risk of institutionalization. In the absence of a curative treatment for dementia, it is essential to have an effective and personalized prevention strategy by identifying the predictive factors for falls in this at-risk population with MCI.\n\nThe research goals of this project are 1) to identify specific predictors for falls in clinic attendees with MCI in preparation for a definitive, fully powered study across France, and 2) to demonstrate the feasibility of a pragmatic fall risk assessment in MCs, whatever its setting and location.\n\nWe aim to prospectively follow-up people diagnosed with MCI and aged above 65 years old in four MCs in France (three in the North (one community-based MC), and one in the Centre) for one year.",[48],[406,407,408,409,410],"Mild Cognitive Impairement","Falls","Predictive factors","Elderly","Gait disorders assessment.",{"date":386,"type":72},{"date":413,"type":72},"2022-09-09",{"date":415,"type":23},"2026-09",{"name":417,"class":79},"University Hospital, Lille",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":17,"sex":18,"minAge":425,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":80},"100473460","investigating-the-neural-correlates-of-cognitive-function-in-psychosis-patients-and-non-psychiatric-controls-with-cannabis-use-100473460","NCT05445180","Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Inclusion Criteria:\n\n* Able to provide informed consent in English or French\n* Heavy cannabis use (defined as weekly cannabis use for at six months) and\u002For DSM-5 diagnosis of CUD\n* Have a Full-Scale IQ ≥ 75\n* Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)\n* Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)\n* Clinically stable (as measured by the PANSS-6, total score \\\u003C30) (psychosis patient arm only)\n\nExclusion Criteria:\n\n* current SUD (other than CUD)\n* MRI contraindications\n* Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine\n* Current suicidal or homicidal ideation\n* Head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* Current medical diseases that requires hospitalization or regular monitoring\n* Being pregnant\n* DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)\n* Taking psychotropic medication","16 Years","80 Years",{"count":428,"type":23},134,[26],"Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.",[432,433,434,435,436,48,437,438],"Psychotic Disorders","Cannabis Use Disorder","Cannabis Dependence","Cannabis Use","Schizophrenia; Psychosis","Memory Impairment","Neuroimaging","2026-05-19",{"date":386,"type":72},{"date":442,"type":72},"2022-04-21",{"date":444,"type":23},"2027-05",{"name":446,"class":79},"Douglas Mental Health University Institute",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":18,"minAge":425,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":24,"phases":455,"briefSummary":456,"conditions":457,"keywords":460,"overallStatus":331,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":470,"locationsCount":80},"100637794","fareon-open-label-device-clinical-trial-100637794","NCT07600320","Fareon Open Label Device Clinical Trial","Microtesla Magnetic Therapy (MMT) Treatment of Cognitive Impairment: Open Label Pilot Study","IncInclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Any sex\u002Fgender\n* 16 years of age or older\n* English Speaking\n* Experiencing symptoms of at least self-reported mild cognitive impairment associated with a confirmed diagnosis of a condition such as Long COVID, Traumatic Brain Injury, other Acquired Brain Injuries, and other neurodegenerative diagnoses including but not limited to Alzheimer's disease\n* Individuals of childbearing age agreeing to use a highly effective form of birth control for the duration of their participation\n* Willing and able to sign informed consent or have a parent or LAR able to sign informed consent form\n* Willing and able to attend all study visits virtually or in person\n\nExclusion Criteria:\n\nIndividual who meets any of the following criteria will be excluded from participation in this study:\n\n* Enrollment in another interventional clinical trial in the last 90 days or during the study period\n* Change in anti-depressant or other psychoactive medication or dose in the last 90 days\n* Cranially implanted devices or metal\n* Pacemaker\n* History of seizure disorder\n* Pregnant or plan to become pregnant during the study as indicated by proof of a positive pregnancy test\n* Inability to achieve appropriate positioning of the study device on the head\n* Any medical, psychiatric, or neurological condition, or concurrent treatment, that in the opinion of the Principal Investigator would interfere with study participation, interpretation of results, or pose additional risk to the participant.",{"count":315,"type":23},[26],"The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis (ME\u002FCFS), and other neurodegenerative diagnoses including but not limited to Alzheimer's disease and to collect data on safety and efficacy to inform the design of larger clinical studies.",[48,458,459],"Acquired Brain Injury","Traumatic Brain Injury",[461,462,463,464],"Long COVID","Myalgic encephalomyelitis\u002FChronic fatigue syndrome","Neurodegenerative","Alzheimer's disease","2026-05-14",{"date":172,"type":72},{"date":468,"type":23},"2026-05-01",{"date":360,"type":23},{"name":471,"class":79},"Icahn School of Medicine at Mount Sinai",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":24,"phases":480,"briefSummary":482,"conditions":483,"keywords":487,"overallStatus":331,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":4},"100485768","phase-1-minocycline-in-neurocognitive-outcomes---sickle-cell-disease-100485768","NCT05605366","Minocycline In Neurocognitive Outcomes - Sickle Cell Disease","MINO-SCD","Inclusion Criteria:\n\nAdults (age ≥ 18 years old) with SCD (HbSS and HbS-β0thalassemia genotypes only) who are followed at the University of Cincinnati Medical Center's SCD clinic are eligible to participate. As hydroxyurea is the standard-of-care in SCD, individuals on hydroxyurea will be included\n\nExclusion Criteria:\n\n1. adults with other SCD genotypes (HbSC or HbS- β+thalassemia),\n2. individuals with a history of overt stroke or other known neurological disorder,\n3. premature birth before 30 weeks gestation,\n4. monthly therapy with chronic blood transfusions,\n5. coexisting autoimmune condition due to an elevated risk for autoimmune-related complications with tetracyclines,\n6. tetracycline allergy.\n7. Women who are pregnant or breast-feeding",{"count":315,"type":23},[481],"PHASE1","Sickle cell disease (SCD) is a common, inherited blood disorder that primarily affects people of African Ancestry. It has a lot of complications including neurological complications. The neurological complications of SCD are particularly devastating and lead to cognitive decline even in the absence of overt brain injury. In such cases, it is thought that inflammation in the brain maybe partly responsible for the cognitive decline.\n\nThe main reasons for this research study are to see 1) how safe and 2) how well minocycline works to try to stop\u002Freverse cognitive decline in people with SCD. People with SCD are at risk for changes in their brain over time that can cause problems with learning, memory, and attention. Part of the reason for this is inflammation within the brain. Minocycline may be able to stop these brain changes by stopping this brain inflammation.\n\nMinocycline is a second-generation tetracycline antibiotic that has been shown to both inhibit neuroinflammation and improve cognitive function in a variety of neurodegenerative and psychiatric disorders but has not yet been studied in SCD. We are proposing here, a pilot double-blinded, randomized controlled trial to examine the tolerability and early efficacy of minocycline in adults with SCD at two dosing regimens (200 mg and 300 mg daily) versus placebo over one year. Participants will undergo a neuropsychological exam using the NIH Toolbox Cognition Battery at both study enrollment and exit (after one year) to assess for changes\u002Fstability of cognition. Participants will receive monthly phone calls\u002Ftext messages to assess for adverse events and will be seen every three months for pill counts and routine laboratory monitoring. The primary outcome will be a comparison of adverse events across the two dosing strategies versus placebo. Early evidence for cognitive benefit will also be assessed from the results of the NIH Toolbox.",[484,325,269,49,48,485,486],"Sickle Cell Disease","Cognitive Deficit","Neuroinflammatory Response",[488,489,490,491],"sickle cell disease","benign hematology","cognitive dysfunction","neuroinflammation","2026-05-11",{"date":465,"type":72},{"date":495,"type":23},"2026-12-01",{"date":497,"type":23},"2028-06-15",{"name":499,"class":79},"University of Cincinnati",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":506,"enrollmentInfo":507,"targetDuration":4,"studyType":24,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":80},"100405345","network-targeted-theta-burst-stimulation-for-episodic-memory-improvement-in-mild-cognitive-impairment-100405345","NCT04558164","Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment","Inclusion Criteria:\n\n* Agreement to participate in the study\n* 55-100 years of age\n* Right-handedness\n* In good general health\n* Living independently\n* Subjective memory complaints (self-report and positive score on MFQ)\n* Katz ADL scale and Lawton iADL scale: We will review scores on a case-by-case basis if they did not score 100%. We will exclude if the scores show impairment in ADLs that suggests problems with independent functioning due to cognitive impairment.\n* MMSE score \\> 24\n* PHQ Depression score =\\\u003C 7\n* Ability to read, write, and speak English fluently\n* Diagnosis of mild neurocognitive disorder according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria. Participants with subjective memory complaints without an aMCI diagnosis will be reviewed on a case-by-case basis based on neuropsychological scores. Participants scoring a raw score of 0 or 3 standard deviations below normative expectations on the long delay recall in two or more of the three tasks (BVMT-R, RCFT, and CVLT-III) will be excluded.\n* No change in use of psychotropic medication for treatment of depression, anxiety, ADHS or psychosis 1 month prior and during the study.\n\nScreening diagnostic criteria for aMCI will be subjective memory complaints, intact instrumental and basic activities of daily living (Smith et al., 1996), PHQ, MMSE, BVMT-R (25-minute delay), CVLT-II (20-minute delay), Rey-Osterrieth Complex Figure Task (30-minute delay). Baseline assessments will include neuropsychological testing of all study subjects.\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* Diagnosis of dementia\n* Active major medical, psychiatric, or neurologic disorder associated with neurocognitive impairment\n* History of alcohol or substance abuse\n* Recent (\\\u003C 6 months) alcohol or substance abuse (excluding nicotine or caffeine)\n* History of stroke (if the stroke in our judgment is related to the memory problem), traumatic brain injury with loss of consciousness, or other neurologic disorder (e.g., epilepsy, Huntington's disease, Parkinson's disease)\n* Non-English speaking participants\n* Not right handed based on self-report or evaluation based on a standard report\n* Has received TMS before (not TMS naïve)\n* Poorly controlled hypertension or cardiovascular disease\n* Current enrollment in a memory-enhancement study or course\n* Contraindication to TMS or MRI including claustrophobia, metal in body, surgery within 60 days, certain implants, or previous abnormal MRI results.\n* scanning facial tattoos is okay if safe with MRI\n* is taking:\n\n  * anticholinergic medication (e.g., Detrol, Cogentin);\n  * sedating antihistamine (e.g., Benadryl);\n  * any drug that has significant anticholinergic or antihistaminic side effects (e.g., tricyclic antidepressant medications, Remeron).\n  * benzodiazepines. While not a strict rule out, this will be decided on a case-by-case basis depending on the dose.","100 Years",{"count":508,"type":23},70,[26],"The purpose of this study is to see if stimulation of the brain can improve memory. The investigators will use a device called transcranial magnetic stimulation that can stimulate and activate a specific part of the brain that is important for memory. The study will enroll MCI subjects and subjects with subjective memory complaints who will be randomly assigned to receive active or sham brain stimulation. 'Blinded' or 'sham-controlled' means that the subject will not know whether the treatment they receive is the active treatment or the non-active stimulation. In the 'sham' condition, the stimulator will turn on but will not actually be stimulating the target brain region.",[48,512],"Memory Disorders in Old Age","2026-04-29",{"date":515,"type":72},"2026-05-05",{"date":517,"type":72},"2021-01-26",{"date":519,"type":23},"2026-06-30",{"name":281,"class":79},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":17,"sex":18,"minAge":528,"maxAge":148,"enrollmentInfo":529,"targetDuration":4,"studyType":24,"phases":531,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":80},"100558115","bwell-d-pilot-randomized-controlled-trial-100558115","NCT06546917","bWell-D Pilot Randomized Controlled Trial","The bWell Cognitive Care Platform: A Pilot Feasibility Study in Patients With Depression","Inclusion Criteria:\n\n* 19-55 years old\n* Meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD as assessed by a standardized psychiatric interview (SCID-5-RV) conducted by a trained clinician.\n* Patients will be euthymic or mildly depressed (defined by a Montgomery-Asberg Depression Rating Scale \\[MADRS\\] score \\\u003C 19)\n* Patients will report subjective cognitive deficits at baseline, as indicated by a total Perceived Deficits Questionnaire - Depression 20 \\[PDQ-D-20\\] score \\> 20 at study enrollment.\n* If using antidepressants, participants will be on stable antidepressant therapy for at least 4 weeks prior to randomization. All concomitant doctor-prescribed medications must be at a stable dose for 4 weeks prior to the randomization visit.\n* If undergoing psychotherapy, participants will be on stable adjunct psychotherapy for at least 8 weeks prior to randomization\n* If comorbid diagnosis of attention deficit hyperactivity disorder (ADHD), patients must be on stable dose of stimulants for at least 4 weeks prior to randomization.\n* Participants will be able to follow written and verbal instructions in English\n\nExclusion Criteria:\n\n* Moderate - severely depressed patients will be excluded at this point due to acceptability concerns (e.g. potential for cybersickness)\n* Presence of significant neurological disorders, head trauma, or other unstable medical conditions. These conditions may adversely impact cognitive functioning and influence study results.\n* Presence of other psychiatric disorder (e.g. anxiety, psychotic disorder) that may be considered primary.\n* Meeting DSM-5 criteria for alcohol or other substance use disorder within three months prior to the randomization visit.\\*\n* Use of benzodiazepine medications more than three times per week and\u002For within 24 hours of baseline or close out visit\n* Use of cannabis or alcohol within 24 hours, or tobacco within 30 minutes of baseline or close out visit\n* Suicidal ideation or self harm\n* Completion of previous cognitive remediation\n\nAdditionally, patients will be excluded from the study if they meet any of the following criteria due to contraindications with MRI scanning:\n\n* Retained wires from an electronic implant that has been removed (i.e. pacemaker wires not attached to a pacemaker)\n* Cardiac pacemaker or defibrillator\n* Metal in eye or orbit\n* Ferromagnetic aneurysm clip\n* Pregnancy\n* Makeup tattoos that are not designed to fade over time\n* Stainless steel intrauterine device (IUD)\n\nDepending on the individual situation, they MAY NOT be able to participate if they have\u002Fhad any of the following:\n\n* Artificial Heart Valve\n* Ear or eye implant\n* Brain aneurysm clip\n* Implanted electronic device (i.e. drug infusion pump, electrical stimulator)\n* Coil, catheter, or filter in any blood vessel\n* Orthopedic hardware (artificial joint, plate, screw, rod)\n* Shrapnel, bullets, or other metal fragments\n* Surgery, medical procedure or tattoos (including tattooed eyeliner) in the last six weeks\n* Other metallic prostheses\n\nIf the participant has any of the above, or any safety issues arise during MRI screening process, the individual case will be reviewed by UBC Hospital MR Technologist and\u002For Radiologist and a case-by-case decision will be made regarding participation.\n\nAdditionally, for the healthy participant recruitment, the eligibility criteria is as follows:\n\nInclusion Criteria for healthy controls:\n\n\\- 19-55 years old\n\nExclusion criteria for healthy controls:\n\n* History of any psychiatric disorder, as assessed by a standardized psychiatric diagnostic interview\n* Presence of significant neurological disorder, head trauma, or other unstable medical conditions which may adversely impact cognitive functioning\n* Presence of any physical mobility issues that limit arm or neck movement","19 Years",{"count":530,"type":23},40,[26],"The goal of this clinical trial is to determine the acceptability, feasibility, and validity of the bWell Cognitive Care Platform for Depression (bWell-D), a novel Virtual Reality (VR) cognitive assessment and remediation tool, in depressed populations. The main questions are:\n\n* Do patients with Major Depressive Disorder (MDD) find the bWell-D cognitive assessment battery and protocol feasible, tolerable, and acceptable?\n* Do patients with Major Depressive Disorder (MDD) find the 8 week bWell-D remediation protocol feasible, tolerable, and acceptable?\n\nFollowing initial cognitive assessment, researchers will assess feasibility outcomes in the bWell remediation arm to a VR scenes experience arm to learn more about the feasibility of bWell for cognitive assessment and remediation.\n\nPatients will:\n\n* Complete an initial bWell cognitive assessment session\n* Randomized to either receive bWell cognitive remediation or a VR scenes experience twice a week for eight weeks\n* Complete cognitive\u002Ffunctional\u002Fclinical assessments and EEG at baseline, midpoint and endpoint of the remediation protocol, as well as two MRI scans and measures of tolerability, engagement, and enjoyment",[534,48],"Depressive Disorder, Major","2026-04-22",{"date":537,"type":72},"2026-04-28",{"date":539,"type":72},"2025-01-01",{"date":541,"type":23},"2026-08",{"name":543,"class":79},"University of British Columbia",{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":18,"minAge":372,"maxAge":426,"enrollmentInfo":551,"targetDuration":4,"studyType":24,"phases":553,"briefSummary":554,"conditions":555,"keywords":556,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":80},"100575721","phase-1-stem-cell-therapy-for-early-alzheimers-disease-100575721","NCT06775964","Stem Cell Therapy for Early Alzheimer's Disease","Mesenchymal Stem Cell Therapy for Early Alzheimer's Disease","Inclusion Criteria:\n\n1. Has signed an informed consent form before any assessment is performed as part of the study.\n2. Be male or female between 60 and 80 years old.\n3. Subject has been or is in process of being clinically diagnosed with late pre-symptomatic or mild cognitive impairment (MCI) due to AD (prodromal AD).\n4. Mini-Mental State Examination (MMSE) score of ≥ 22\n5. Has an MRI to evaluate AD pathology (may use previous if within 6mo.)\n6. Has APOE status to evaluate AD pathology (may use previous result)\n7. Proficiency in English is required because cognitive tests are administered in English only.\n8. Has evidence of brain amyloidosis via PET Scan or Aβ42\u002F40 ratios in CSF.\n9. Has evidence of peripheral inflammatory profile based on CRP (≥ 8 mg\u002FL), IL-6 (≥ 3.1 pg\u002FmL), TNF-α (10 pg\u002FmL), or erythrocyte sedimentation rate (ESR) (≥20 mm\u002Fh) in blood assays.\n10. Is in the opinion of the Investigator, in good general medical health based upon medical history, physical examination, laboratory tests, vital signs and EKG.\n\nExclusion Criteria:\n\n1. Current medical or neurological condition that might impact cognition or performance on cognitive assessments. (e.g., traumatic brain injury (TBI), Parkinson's disease (PD), multiple sclerosis, etc.)\n2. Inability or unwillingness of patient to undergo neuropsychological testing.\n3. Advanced, severe, progressive or unstable disease that may interfere with the safety, tolerability and study assessments, or put the subject at special risk. (e.g., significant cardiac disease, severe renal impairment, severe hepatic impairment, autoimmune disease, etc.)\n4. History of malignancy of any organ system within the past 60 months, that in the opinion of the investigator would impede evaluation or interpretation of subject safety or study results.\n5. Females of childbearing potential must not be pregnant.\n6. Inability or unwillingness to undergo PET Scans.\n7. Inability or unwillingness to undergo MRI Scans.\n8. Positive blood test for either HIV, Hepatitis B, Hepatitis C or Syphilis\n9. Positive for TSPO SNP rs6971\n10. Inability or unwillingness to undergo Lumbar Punctures.\n11. Inability or unwillingness to undergo infusions.\n12. Any condition, which in the opinion of the investigator, would put the subject at undue risk or would interfere with evaluation of the investigational product or interpretation of subject safety or study results.",{"count":552,"type":23},12,[481,153],"The goal of this clinical trial is to learn if stem cell therapy works to treat brain inflammation in adults. Inflammation in the brain may be involved in adults who have memory or thinking problems. The stem cells will be taken from participant's fat samples, processed and given back to participants, so they are their own donor. The main questions this trial aims to answer are:\n\n* Does stem cell therapy reduce inflammation in the brain?\n* Does stem cell therapy improve brain activity?\n* Does stem cell therapy slow down progression to Alzheimer's disease?\n\nParticipants will:\n\n* Have a small fat biopsy taken at a doctor's office to process stem cells\n* Receive 4 infusions of stem cells, through a vein in the arm over 12 weeks\n* Visit the clinic every 2-4 weeks for the first 4 months and then every 1-2 months for 8 months for checkups and tests",[48],[160,269,464],"2026-04-17",{"date":559,"type":72},"2026-04-20",{"date":561,"type":72},"2026-03-11",{"date":563,"type":23},"2028-01",{"name":565,"class":79},"Paul E Schulz",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":17,"sex":18,"minAge":573,"maxAge":346,"enrollmentInfo":574,"targetDuration":4,"studyType":24,"phases":575,"briefSummary":576,"conditions":577,"keywords":582,"overallStatus":331,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":4},"100595156","virtual-mindfulness-and-breathing-training-for-stress-burnout-sleep-and-cognition-in-rotating-shift-nurses-100595156","NCT07028788","Virtual Mindfulness and Breathing Training for Stress, Burnout, Sleep, and Cognition in Rotating-Shift Nurses","Effectiveness of Virtual Mindfulness Combined With Brief Structured Breathing Training on Perceived Stress, Burnout, Sleep Quality, and Cognitive Function Among Rotating-Shift Nurses: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age between 20 and 65 years.\n2. Able to understand spoken or written Mandarin or Taiwanese.\n3. Employed full-time for at least 3 months with a signed employment contract.\n4. Has worked rotating shifts (including day, evening, and\u002For night shifts) in the past 3 months.\n5. Willing to participate and sign informed consent.\n6. Registered nurse.\n7. A perceived stress score greater than or equal to 50 based on a standardized scale.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding individuals.\n2. History of substance abuse (e.g., tobacco, illicit drugs).\n3. Alcohol consumption ≥350 ml\u002Fweek with alcohol content ≥3.5%.\n4. Diagnosed or suspected autonomic nervous system disorders.\n5. History of severe or unstable cardiovascular disease, cerebrovascular disease, cancer, or end-stage organ failure within the past 6 months.\n6. Current diagnosis of psychiatric disorders (e.g., major depressive disorder, schizophrenia), or use of psychiatric or sleep medications (e.g., antidepressants, sedatives).\n7. Reported discomfort (e.g., dizziness, nausea) when using virtual reality devices.\n8. Engaged in other regular exercise programs, light therapy, or mind-body interventions during the study period.\n9. Participating in other clinical trials simultaneously.","20 Years",{"count":265,"type":23},[26],"This randomized controlled trial aims to evaluate the effectiveness of a mobile- and virtual reality-based mindfulness and breathing intervention on stress, burnout, sleep quality, and cognitive function among Rotating-shift nurses. Participants will be randomly assigned to one of four groups: (1) health education control group, (2) mobile-based mindfulness only, (3) mobile-based mindfulness combined with brief structured breathing, and (4) virtual reality-assisted mindfulness combined with brief structured breathing. The intervention will last for 8 weeks, with participants practicing 5 times per week for 10 minutes per session. Primary outcomes include perceived stress, burnout levels, sleep quality, and cognitive function.",[578,579,580,48,581],"Occupational Burnout","Work-Related Stress","Sleep Disturbance","Shift Work Disorder",[583,584,585,586,587,588,589,590,591,592],"breathing training","burnout","cognitive function","mindfulness meditation","mobile health","perceived stress","physiological arousal","rotating-shift nurse","sleep quality","virtual reality","2026-04-07",{"date":595,"type":72},"2026-04-08",{"date":597,"type":23},"2026-07",{"date":599,"type":23},"2027-12",{"name":601,"class":79},"Chang Shih-Chin",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":24,"phases":610,"briefSummary":611,"conditions":612,"keywords":614,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":624,"locationsCount":80},"100523408","long-covid-brain-fog-cognitive-rehabilitation-trial-100523408","NCT06095297","Long COVID Brain Fog: Cognitive Rehabilitation Trial","Technique to Enable Return-to-Work by Employees With Long COVID Brain Fog","Inclusion Criteria:\n\n* \\>3 months post COVID\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* impairment in performance of daily activities\n* reside in community\n* reliable transportation to lab\n* sufficiently mentally and physically fit\n* adequate sight and hearing\n* ability to follow directions, and retain information\n* sufficient English proficiency\n\nExclusion Criteria:\n\n* cognitive impairment due to developmental disability, psychiatric disorder, or substance abuse, TBI or progressive brain disease\n* stroke prior to the onset of COVID\n* current substance abuse disorder\n* prior cognitive processing speed training on DoubleDecision or similar program\n* cannot tolerate trans-auricular vagus nerve stimulation",{"count":315,"type":23},[26],"This study will compare two approaches to cognitive rehabilitation in adults with long COVID with persistent, mild to moderate, cognitive impairment. One approach will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) in-lab training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation (VNS), i.e., trans-auricular VNS (taVNS). Component B will include work-related tasks. This approach is termed Constraint-Induced Cognitive Therapy (CICT). The other approach will feature (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, healthy nutrition, and healthy sleep, (C) procedures designed to promote integration of these lifestyle changes into everyday life, and (D) taVNS. This approach is termed Brain Fitness Training (BFT).\n\nA subset of participants, who qualify for and and desire vocational rehabilitation (VR), will receive VR from the Alabama Department of Rehabilitation Services (ADRS) in addition to CICT or BFT. ADRS VR will include career counseling, prescription of on-the-job accommodations, and guidance on return-to-work. Those in the CICT + VR group will also receive on-the-job coaching from a peer mentor for a month after completing training.\n\nCICT, with or without VR, will involve 30 hours of training. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors and the procedures designed to promote transfer of therapeutic gains to daily life and improving skills essential to work; the set of the latter procedures is termed the Transfer Package. ta-VNS will administered for 10 minutes before gaming and in-lab target behavior training. To accommodate the demands of participants' other activities, training sessions will be permitted to be scheduled as tightly as every weekday over 2 weeks or as loosely as every other weekday or so over 4 weeks. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life.\n\nBFT, with or without VR, will involve 30 hours of training following the same schedule as for CICT. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors (healthy sleep, nutrition and relaxation habits) and the procedures designed to promote transfer of behavior change to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life.\n\nParticipants will be randomly assigned to the interventions. Randomization will be stratified by whether participants qualify for and desire VR from ADRS or not. If yes, participants will be randomized in equal numbers to CICT + VR or BFT + VR. If no, participants will be randomized in equal numbers to CICT or BFT.\n\nTesting will happen one month before treatment, one day before treatment, one day afterwards, and 6-months afterwards. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life. Another important outcome measure will be whether or not participants were able to return back to work or had significant improvements in their work activities.",[461,324,325,48,613],"Post-Acute COVID-19 Syndrome",[461,324,325,615,616,617,329],"Vocational Rehabilitation","COVID-19","PASC","2026-04-06",{"date":620,"type":72},"2026-04-13",{"date":622,"type":72},"2024-04-25",{"date":599,"type":23},{"name":338,"class":79},{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":18,"minAge":633,"maxAge":426,"enrollmentInfo":634,"targetDuration":4,"studyType":24,"phases":636,"briefSummary":637,"conditions":638,"keywords":642,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":80},"100632711","tavns--cct-for-neurocognitive-rehab-100632711","NCT07517237","taVNS + CCT for Neurocognitive Rehab","Combining At-Home Transcutaneous Auricular Vagus Nerve Stimulation and Computerized Cognitive Training for Neurocognitive Rehabilitation","NeuroHUB","Inclusion Criteria:\n\ni. Ages 45-80 (inclusive) ii. Adequate sensorimotor function (including motor function of dominant hand to complete CCT) and verbal expressive abilities to complete all assessments.\n\niii. Access to reliable Wi-Fi and a Bluetooth-enabled mobile phone or tablet with internet connection capable of supporting study procedures.\n\niv. Self-reported change in cognitive functioning (e.g., memory, attention, thinking abilities) compared to prior functioning, persisting ≥ 6 months and associated with concern and\u002For impact on daily functioning.\n\nv. Is on fixed pharmacotherapy (i.e. stable dose of medication\u002Fs) for ≥ 4 weeks before enrollment, and expected to remain stable throughout study participation. This includes, but is not limited to, cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants.\n\nExclusion Criteria:\n\ni. Prior diagnosis of Mild Cognitive Impairment or Dementia (NIA-AA) or Mild or Major Neurocognitive Disorder (DSM-5).\n\nii. taVNS contraindications (e.g., history of seizures, history of trauma or damage to ear, reduced\u002Fimpaired sensation in the ear).\n\niii. MRI contraindications (e.g., ferromagnetic implants, claustrophobia). iv. Presence of a neurological, medical, or psychiatric condition that is acute, unstable, or severe, and that, in the judgment of the study investigators, would significantly interfere with safe participation, valid assessment of cognition or mood, or interpretation of study outcomes.\n\nv. Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days that may impact cognition or mood.\n\nvi. For female participants, a positive pregnancy test if still menstruating within the past 12 months.","45 Years",{"count":635,"type":23},20,[26],"The purpose of this study is to investigate whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with computerized cognitive training might help improve thinking abilities and mood. Participants will self-administer these treatment in their homes and undergo pre- and post-treatment assessments of thinking abilities and mood and brain MRIs.",[639,640,641,48],"Psychosocial Well-being","Neurocognitive Function","Cognitive Complaint",[643,48,644,384,586],"Transcutaneous Auricular Vagus Nerve Stimulation","Psychosocial Function","2026-04-03",{"date":595,"type":72},{"date":648,"type":72},"2026-03-12",{"date":650,"type":23},"2026-09-15",{"name":392,"class":79},{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":658,"eligibilityCriteria":659,"healthyVolunteers":12,"sex":18,"minAge":660,"maxAge":426,"enrollmentInfo":661,"targetDuration":4,"studyType":24,"phases":663,"briefSummary":664,"conditions":665,"keywords":668,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":80},"100577087","effectiveness-of-televr-app-in-cognitive-decline-and-mci-patients-100577087","NCT06793735","Effectiveness of TeleVR App in Cognitive Decline and MCI Patients","Effectiveness of Telerehabilitation Plus Virtual Reality App in Patients With Subjective Cognitive Decline, and Mild Cognitive Impairment","TeleVR24","Inclusion Criteria:\n\n* Subjects diagnosed with MCI (AD and PD) according to the criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA, Albert et al., 2011)\n* Subjects diagnosed with SCD according to diagnostic criteria proposed in research settings (Molinuevo et al., 2017)\n* All enrolled subjects must be aged between 40 and 80 years and have at least 5 years of education\n\nExclusion Criteria:\n\n* Presence of psychiatric disorders (major depression, psychosis, anxiety disorders)\n* Presence of severe dementia\n* History of cerebral ischemia\n* Contraindications to brain MRI: pregnant women, pacemakers, non-latest-generation metal joint prostheses, electrodes, neurostimulators, or prostheses that may interfere with magnetic fields, unless there is a written statement of suitability from the specialist who performed the intervention","40 Years",{"count":662,"type":23},480,[26],"The goal of this clinical trial is to evaluate the effectiveness of a telerehabilitation program combined with a virtual reality (VR) app in improving cognitive performance and social skills in patients with Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI).\n\nThe main questions it aims to answer are:\n\nCan a VR telerehabilitation program improve cognitive functions and social skills in patients with SCD and MCI? Are there measurable changes in brain activity, eye movements, and gait patterns after the intervention? Researchers will compare telerehabilitation with a VR group (Experimental Group - EG) to a traditional paper-based cognitive rehabilitation group (Active Control Group - aCG) to determine which approach is more effective.\n\nParticipants will:\n\nUndergo an initial assessment, including neurological exams, neuropsychological tests, brain MRI, EEG, eye movement analysis, and gait evaluation.\n\nParticipate in a 6-week intervention program:\n\nEG: Use VR apps on smartphones\u002Ftablets at home, guided remotely by a therapist. aCG: Perform traditional cognitive exercises using paper-based tasks. Complete follow-up assessments immediately after the intervention and again after three months.\n\nThis study will help determine whether telerehabilitation with VR can provide measurable cognitive and social benefits, contributing to improved care strategies for individuals at risk of dementia.",[48,666,160,167,667],"Subjective Health","Parkinson Disease",[669,670,378,671,329],"Telerehabilitation","Virtual Reality (VR)","Subjective Cognitive Decline (SCD)","2026-04-02",{"date":645,"type":72},{"date":675,"type":72},"2025-01-08",{"date":677,"type":23},"2026-12-31",{"name":679,"class":79},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":686,"eligibilityCriteria":687,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":660,"enrollmentInfo":688,"targetDuration":4,"studyType":24,"phases":689,"briefSummary":690,"conditions":691,"keywords":697,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":704,"lastUpdatePostDateStruct":705,"startDateStruct":707,"completionDateStruct":709,"leadSponsor":711,"locationsCount":80},"100598614","probiotic-impact-on-cognitive-performance-and-metabolic-outcomes-in-overweight-young-adults-with-impaired-glucose-regulation-100598614","NCT07073781","Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation","A Double-blind Placebo-controlled Exploratory Trial to Assess the Impact of Daily Lab4P Probiotic Supplementation on Cognitive Performance and Metabolic Regulation in Overweight Young Adults With Impaired Glucose Regulation","ProCog","Inclusion Criteria\n\n* Aged 18-40 years\n* Body Mass Index (BMI) between 25.0 and 29.9 kg\u002Fm² (classified as overweight)\n* In good general health (self-reported)\n* Normal self-reported sleep patterns, with no history of diagnosed sleep disorders\n* Willing and able to provide informed consent\n* Able to comply with study procedures, including fasting and oral glucose tolerance testing\n\nExclusion Criteria:\n\n* Diagnosed diabetes (any type).\n* Diagnosed sleep disorders.\n* Fasting glucose \\>6.9 mmol\u002FL during screening.\n* History of bariatric surgery (e.g., gastric bypass, sleeve gastrectomy).\n* Major surgery, significant illness, trauma, infection, or myocardial infarction within the past 6 weeks.\n* Current use of medications affecting glucose metabolism or probiotics\n* Pregnancy or actively trying to conceive\n* Night shift work within the past month",{"count":508,"type":23},[26],"This 12-week, double-blind, placebo-controlled trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight adults aged 18 to 40 with impaired glucose tolerance, a preclinical condition where blood glucose regulation is mildly disrupted. Seventy participants will be randomly assigned to receive either Lab4P or a placebo. The study will assess changes in memory, executive function, and processing speed, along with blood glucose control, cardiovascular function, cholesterol levels, body composition, and markers of inflammation. The study will also analyse changes in the gut microbiome and evaluate the safety and tolerability of the probiotic.",[692,693,694,695,48,696],"Impaired Glucose Regulation","Impaired Glucose Tolerance (Prediabetes)","Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)","Overweight (BMI > 25)","Neurovascular Coupling Mechanism and Cognitive Function",[698,699,700,701,702,703],"Probiotic supplementation","Psychobiotic","Cognitive performance","Metabolic function","Impaired glucose tolerance","Gut-brain axis","2026-03-25",{"date":706,"type":72},"2026-03-31",{"date":708,"type":72},"2025-08-15",{"date":710,"type":23},"2026-08-20",{"name":712,"class":79},"Leeds Beckett University",{"id":714,"slug":715,"hasResults":12,"nctId":716,"briefTitle":717,"officialTitle":718,"acronym":4,"eligibilityCriteria":719,"healthyVolunteers":12,"sex":18,"minAge":372,"maxAge":4,"enrollmentInfo":720,"targetDuration":4,"studyType":24,"phases":722,"briefSummary":723,"conditions":724,"keywords":728,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":731,"lastUpdatePostDateStruct":732,"startDateStruct":734,"completionDateStruct":736,"leadSponsor":738,"locationsCount":80},"100606123","cognitive-remediation-100606123","NCT07171450","Cognitive Remediation","Computerized Cognitive Remediation of Postviral Neurocognitive Dysfunction in Older Adults","Inclusion Criteria:\n\n* age ≥ 60 years old\n* prior history of COVID-19 that was confirmed with viral testing (e.g., positive laboratory test or positive at-home rapid test)\n* cognitive symptoms (e.g., memory or thinking concerns) following COVID- 19 infection that have lasted for at least 12 weeks and are still present\n* clinically meaningfully subjective cognitive concerns (i.e., T-score \\\u003C 40) on the PROMIS-Cognitive Function Scale\n* objective evidence of cognitive decline\\*, as defined by performance on standardized measures of executive functioning, memory, or processing speed from the NIH Toolbox Cognition Battery that is at least 1 standard deviation below estimated premorbid cognitive functioning \\[\\*at least one third of the sample, or 25 out of 75 subjects, will be required to meet this inclusion criterion\\]\n* fluent in English language\n* off psychiatric medication or on a stable dose for at least 8 weeks\n\nExclusion Criteria:\n\n* history of neurological disorder with potential to interfere with study participation or confound results (e.g., uncontrolled seizure disorder, moderate to severe traumatic brain injury or stroke with persistent neurological deficits)\n* history of dementia and\u002For dementia range performance on the Mini- Mental State Examination (i.e., score of less than or equal to 23)\n* prior diagnosis of Mild Cognitive Impairment (MCI) or Mild Neurocognitive Disorder unrelated to the participant's history of COVID-19\n* history of severe psychiatric illness that may interfere with study participation or confound results (e.g., bipolar disorder, schizophrenia, or other psychotic disorder)\n* history of significant neurodevelopmental condition that may interfere with study participation or confound results (e.g., intellectual disability, autism spectrum disorder, or specific learning disorder with impairment in reading)\n* alcohol or other substance use disorder within the past 2 years\n* significant sensory impairments (e.g., blindness) that would interfere with the ability to complete neuropsychological measures or engage in the tablet-based intervention\n* performance that is below expectation on a test of effort and validity",{"count":721,"type":23},75,[26],"The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation (\"brain training\") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are:\n\n* Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction?\n* Will treatment effects be maintained over time, leading to better long term cognitive outcomes?\n* Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement?\n* Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction.\n\nParticipation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including:\n\n* Initial intake visit: Eligibility confirmation (\\~2-3 hours)\n* Computer activities: About 5 hours per week for \\~6 weeks (total \\~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase\n* Weekly remote check-in meetings: \\~30 minutes each during treatment\n* Blood draws: Two sessions (before and after treatment), \\~20-30 minutes each\n* Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)",[101,725,717,48,726,727],"Inflammation","Postviral Syndrome","Digital Medicine",[101,725,717,729,726,730],"Cognitive dysfunction","digital medicine","2026-02-20",{"date":733,"type":72},"2026-02-24",{"date":735,"type":72},"2026-01-21",{"date":737,"type":23},"2030-02-28",{"name":739,"class":79},"Cutter Lindbergh",{"id":741,"slug":742,"hasResults":12,"nctId":743,"briefTitle":744,"officialTitle":745,"acronym":746,"eligibilityCriteria":747,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":748,"enrollmentInfo":749,"targetDuration":751,"studyType":187,"phases":4,"briefSummary":752,"conditions":753,"keywords":756,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":765,"lastUpdatePostDateStruct":766,"startDateStruct":768,"completionDateStruct":770,"leadSponsor":772,"locationsCount":80},"100625082","the-liver-cirrhosis-cognitive-decline-scale-liccos-100625082","NCT07418008","The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)","Development and Psychometric Validation of The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)","LiCCoS","Inclusion Criteria:\n\n* Age 18-75 years.\n* Documented clinical diagnosis of liver cirrhosis based on imaging, histology, or validated clinical criteria.\n* Able to read and understand the language of the cognitive tests.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>75 years\n* Known case of Overt Hepatic Encephalopathy defined as Grade II or higher on the West Haven criteria \\[25\\].\n* Use of central nervous system depressants, anticholinergics, or psychotropics initiated or changed within the past 4 weeks.\n* Known case of Severe uncorrected visual or hearing impairment limiting ability to complete cognitive testing.\n* Known case of Any neurological and psychological disorders, substance use disorder and sleep disorders.\n* Known case of Severe systemic illness (e.g., end-stage renal disease, decompensated heart failure) that may independently impair cognition or limit participation.","75 Years",{"count":750,"type":23},230,"1 Day","The goal of this observational study is to develop and test a new questionnaire called the Liver Cirrhosis Cognitive Decline Scale (LiCCoS) for adults with liver cirrhosis. This questionnaire is designed to help identify problems with thinking and daily mental functioning that are common in people with liver cirrhosis but are often missed during routine care.\n\nPeople with liver cirrhosis may experience problems such as forgetfulness, slowed thinking, trouble paying attention, or difficulty planning everyday tasks. These problems can affect daily life, safety, and treatment adherence. Existing cognitive tests often require special training or equipment and may not fully reflect how people experience these difficulties in daily life. This study aims to create a simple, patient-reported tool that captures these concerns in an easy and practical way.\n\nThe main questions this study aims to answer are:\n\n1. Can the LiCCoS questionnaire reliably measure cognitive difficulties in adults with liver cirrhosis?\n2. Does the questionnaire correctly reflect differences in cognitive function across levels of liver disease severity?\n3. Do LiCCoS scores relate to results from commonly used cognitive screening tests?\n\nParticipants will be adults aged 18 to 75 years who have a confirmed diagnosis of liver cirrhosis and are attending outpatient clinics. Participation is voluntary.\n\nParticipants will:\n\nProvide basic background information, such as age and medical history\n\nComplete the LiCCoS questionnaire about their thinking and daily mental functioning\n\nComplete standard cognitive screening tests commonly used in clinical care\n\nThis study does not involve any treatment or change in medical care. The information collected will be used only for research purposes. The results are expected to help develop a reliable and easy-to-use tool that can support early recognition of cognitive difficulties in people with liver cirrhosis and improve communication between participants and health care providers.",[754,48,755,165],"Liver Cirrhosis","Hepatic Encephalopathy",[746,757,758,729,759,760,761,762,763,764],"Liver cirrhosis","Cognitive impairment","Hepatic encephalopathy","Patient-reported outcome measure","Psychometric validation","Scale development","Cognitive assessment","Chronic liver disease","2026-02-10",{"date":767,"type":72},"2026-02-18",{"date":769,"type":72},"2025-12-15",{"date":771,"type":23},"2026-11-30",{"name":773,"class":79},"University of Malaya",{"id":775,"slug":776,"hasResults":12,"nctId":777,"briefTitle":778,"officialTitle":779,"acronym":780,"eligibilityCriteria":781,"healthyVolunteers":12,"sex":18,"minAge":89,"maxAge":782,"enrollmentInfo":783,"targetDuration":4,"studyType":24,"phases":784,"briefSummary":785,"conditions":786,"keywords":787,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":790,"lastUpdatePostDateStruct":791,"startDateStruct":793,"completionDateStruct":795,"leadSponsor":796,"locationsCount":80},"100624740","feasibility-safety-and-preliminary-efficacy-of-median-nerve-stimulation-for-cognitive-dysfunction-in-patients-with-acute-traumatic-brain-injury-100624740","NCT07413562","Feasibility, Safety, and Preliminary Efficacy of Median Nerve Stimulation for Cognitive Dysfunction in Patients With Acute Traumatic Brain Injury","Feasibility, Safety, and Preliminary Efficacy of Median Nerve Stimulation for Cognitive Dysfunction in Patients With Acute Traumatic Brain Injury (MARS-TBI): Study Protocol for a Pilot Randomized Controlled Trial","MARS-TBI","Inclusion Criteria:\n\n1. Aged 18-64 years.\n2. Admitted within 3 days post-injury with a Glasgow Coma Scale (GCS) score of 9-12 at admission, accompanied by imaging abnormalities.\n3. Presence of cognitive dysfunction assessed within 1-week after injury, with a Mini-Mental State Examination (MMSE) score ≤26.\n4. Pre-injury Clinical Dementia Rating (CDR) score = 0 as reported by family members.\n5. With a pre-injury education of ≥6 years, able to comprehend instructions and cooperate in completing scale assessments, magnetic resonance imaging (MRI), and magnetoencephalography (MEG) examinations.\n\nExclusion Criteria:\n\n1. Requirement for emergent neurosurgical intervention during treatment including surgery, intracranial pressure monitoring device placement, or drainage catheter insertion.\n2. Unstable vital signs or hemodynamics, or presence of unstable cardiac, pulmonary, hepatic, renal, or hematopoietic system disorders.\n3. Pre-existing central nervous system conditions causing cognitive decline: traumatic brain injury, intracranial infection, brain tumor, epilepsy, stroke, neurodegenerative diseases, carbon monoxide poisoning, and alcohol abuse.\n4. Inability to complete assessments or examinations due to severe visual or auditory impairment, severe psychiatric or behavioral disorders, MRI contraindications, and MEG intolerance.\n5. Short life expectancy due to critical illnesses.\n6. Right forearm with extensive skin lesions or scars, right median nerve injury, brachial plexus injury, cervical spinal cord injury, or intolerance to MNS.\n7. Pregnant or lactating women.\n8. Participation in other ongoing clinical trials.","64 Years",{"count":315,"type":23},[26],"Currently, the treatment of cognitive dysfunction after acute TBI remains a challenge, and novel therapeutic methods are urgently needed. Median nerve stimulation (MNS) is a non-invasive neuromodulation technique and recently has shown positive effects in awaking coma of acute brain injury. It has been shown to improve cognition in healthy volunteers and may be a potential therapeutic approach for cognitive dysfunction in patients with acute TBI. Therefore, the main purpose of the study is to evaluate the feasibility, safety, and preliminary efficacy of MNS for cognitive dysfunction in patients with acute TBI.",[459,48],[459,729,788,789],"Median nerve stimulation","Neuromodulation","2026-02-09",{"date":792,"type":72},"2026-02-17",{"date":794,"type":72},"2025-02-01",{"date":677,"type":23},{"name":797,"class":79},"Beijing Tiantan Hospital"]